CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
30 hedge funds and large institutions have $5.66M invested in CASI Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
11% more funds holding
Funds holding: 27 → 30 (+3)
2% less capital invested
Capital invested by funds: $5.8M → $5.66M (-$138K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$188K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$25.2K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$16.9K |
| 4 |
EHC
Everett Harris & Co
Los Angeles,
California
|
+$16.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
-$81.6K |
| 2 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$27K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.68K |
| 4 |
EEG
E.E. Geduld
|
-$8.46K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$8K |
CASI Hedge Fund Activity: Q4 2013 in Review
30 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2013, worth a combined $5.66M — down 2.4% from $5.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CASI positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, adding an estimated $188K. The largest seller was Wellington Shields Capital Management, cutting an estimated $81.6K.
- 30 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2013, up from 27 in Q3 2013.
- Funds reported $5.66M of CASI Pharmaceuticals stock for Q4 2013, down 2.4% quarter-over-quarter.
- 7 funds opened new CASI Pharmaceuticals positions in Q4 2013 and 4 closed out, a net change of +3 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2013 was Sabby Management, an estimated $188K added.
- The largest CASI Pharmaceuticals seller in Q4 2013 was Wellington Shields Capital Management, an estimated $81.6K sold.
Based on aggregated 13F filings for Q4 2013.